DaVita said that during Q2 2025 it experienced a cybersecurity incident that resulted in a temporary disruption of its operations, and incurred charges of approximately $13.5 million to remediate the incident and restore systems. Patient care costs increased by $1.0 million and general and administrative expenses increased by $12.5 million. The company added that these costs do not include the impact related to business interruption on its results.

10-QQuarterly reportFiled Aug 5, 2025Period of report Jun 30, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

DaVita said that during Q2 2025 it experienced a cybersecurity incident that resulted in a temporary disruption of its operations, and incurred charges of approximately $13.5 million to remediate the incident and restore systems. Patient care costs increased by $1.0 million and general and administrative expenses increased by $12.5 million. The company added that these costs do not include the impact related to business interruption on its results.
DaVita said that net cash provided by operating activities for the 6 months ended June 30, 2025 decreased compared to the prior year period. The company cited decreased operating results due to increased debt expense and increased accounts receivable from delayed collections related to the cybersecurity incident as factors. Free cash flow also decreased.
DaVita said that for the 6 months ended June 30, 2025 it raised $1,000 million through the issuance of 6.75% Senior Notes. The company also said it repaid $93 million of interest-free borrowings related to UnitedHealth Group during the same period and repurchased 6.7 million shares of common stock.
DaVita said that for the 6 months ended June 30, 2025 U.S. dialysis average patient service revenue per treatment increased compared to the prior year period. The company cited the incorporation of phosphate binders into the ESRD PPS bundle and Medicare base rate increases as factors. Patient care costs per treatment also increased.

Key figures

Quarter ended June 30, 2025

Revenue: $3.4B
Operating income: $538M
Net income: $199M
EPS: $2.58

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q2 Cybersecurity Incident-Related Charges

DaVita said that during Q2 2025 it experienced a cybersecurity incident that resulted in a temporary disruption of its operations, and incurred charges of approximately $13.5 million to remediate the incident and restore systems. Patient care costs increased by $1.0 million and general and administrative expenses increased by $12.5 million. The company added that these costs do not include the impact related to business interruption on its results.

Source · Based on the MD&A text of the filing

6-Month Operating Cash Flow and Free Cash Flow Decrease

DaVita said that net cash provided by operating activities for the 6 months ended June 30, 2025 decreased compared to the prior year period. The company cited decreased operating results due to increased debt expense and increased accounts receivable from delayed collections related to the cybersecurity incident as factors. Free cash flow also decreased.

Source · Based on the MD&A text of the filing

6.75% Senior Notes Issuance and Use of Proceeds

DaVita said that for the 6 months ended June 30, 2025 it raised $1,000 million through the issuance of 6.75% Senior Notes. The company also said it repaid $93 million of interest-free borrowings related to UnitedHealth Group during the same period and repurchased 6.7 million shares of common stock.

Source · Based on the MD&A text of the filing

U.S. Dialysis Average Patient Service Revenue and Patient Care Costs Per Treatment

DaVita said that for the 6 months ended June 30, 2025 U.S. dialysis average patient service revenue per treatment increased compared to the prior year period. The company cited the incorporation of phosphate binders into the ESRD PPS bundle and Medicare base rate increases as factors. Patient care costs per treatment also increased.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.